Protalix BioTherapeutics, Inc.
$2.27
▼
-1.83%
2026-04-21 08:53:00
www.protalix.com
ASE: PLX
Explore Protalix BioTherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$184.11 M
Current Price
$2.27
52W High / Low
$3.19 / $1.32
Stock P/E
—
Book Value
$0.6
Dividend Yield
—
ROCE
-9.85%
ROE
-14.44%
Face Value
—
EPS
$-0.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
226
Beta
-0.09
Debt / Equity
17.25
Current Ratio
2.51
Quick Ratio
1.54
Forward P/E
3.71
Price / Sales
3.51
Enterprise Value
$163.36 M
EV / EBITDA
-40.49
EV / Revenue
3.1
Rating
None
Target Price
$11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 2. | Oncolytics Biotech Inc. | $1.11 | — | $163.05 M | — | -1939.57% | 11480.64% | $1.85 / $0.45 | $0 |
| 3. | PMGC Holdings Inc. | $3.32 | — | $6.35 M | — | -76.42% | -1.07% | $309.12 / $1.62 | $97.11 |
| 4. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 5. | Edgewise Therapeutics, Inc. | $33.97 | — | $3.69 B | — | -36.44% | -34.19% | $35 / $12.15 | $4.92 |
| 6. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 7. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 9.12 M | 17.85 M | 15.66 M | 10.11 M | 18.22 M | — |
| Operating Profit | -4.66 M | 2.13 M | 1.17 M | -4.14 M | 7.21 M | — |
| Net Profit | -5.5 M | 2.35 M | 0.16 M | -3.62 M | 6.49 M | — |
| EPS in Rs | -0.07 | 0.03 | 0 | -0.04 | 0.08 | 0.03 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 52.74 M | 53.4 M | 65.49 M | 47.64 M |
| Operating Profit | -5.5 M | 3.92 M | 10.46 M | -13.01 M |
| Net Profit | -6.6 M | 2.93 M | 8.31 M | -14.93 M |
| EPS in Rs | -0.08 | 0.04 | 0.1 | -0.19 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 82.35 M | 73.42 M | 84.43 M | 55.79 M |
| Total Liabilities | 34.12 M | 30.21 M | 50.87 M | 66.43 M |
| Equity | 48.23 M | 43.21 M | 33.57 M | -10.64 M |
| Current Assets | 66.67 M | 60.08 M | 69.93 M | 44.88 M |
| Current Liabilities | 26.52 M | 25.62 M | 45.53 M | 32.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.99 M | 8.67 M | -1.32 M | -25 M |
| Investing CF | -2.37 M | 4.22 M | -16.71 M | -5.04 M |
| Financing CF | 9.33 M | -16.79 M | 24.67 M | 8.24 M |
| Free CF | -13.63 M | 7.39 M | -2.47 M | -25.63 M |
| Capex | -1.64 M | -1.28 M | -1.15 M | -0.63 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -1.23% | -18.47% | 37.48% | — |
| Earnings Growth % | -325.24% | -64.73% | 155.68% | — |
| Profit Margin % | -12.52% | 5.49% | 12.69% | -31.33% |
| Operating Margin % | -10.43% | 7.34% | 15.97% | -27.32% |
| Gross Margin % | 48.82% | 54.46% | 64.91% | 58.87% |
| EBITDA Margin % | -5.6% | 12.21% | 19.75% | -22.63% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.